Radionuclide 177Lu-Dotatate Improves QoL in Patients with Neuroendocrine Tumors Interview with:

Jonathan Strosberg MD Moffitt Cancer Center Tampa, FL

Dr. Strosberg

Jonathan Strosberg MD
Moffitt Cancer Center, Tampa, FL What is the background for this study?

Response: Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life. We assessed the impact of 177Lu-Dotatate treatment on time to deterioration in health-related quality of life in patients with advanced midgut neuroendocrine tumors in the NETTER-1 study.

Continue reading